VRTN: A Potential Drug Target for Osteoarthritis Type II (G55237)

Target Name: VRTN

NCBI ID: G55237

VRTN

VRTN: A Potential Drug Target for Osteoarthritis Type II

Vertebrae Development Associated (VRTN), also known as Osteoarthritis Type II (OA2), is a protein that is expressed in the articular cartilage of individuals with osteoarthritis (OA). It is a key player in the development and maintenance of articular cartilage, and has been identified as a potential drug target for the treatment of OA2.

The vertebrae is a crucial part of the skeleton, and is responsible for providing support and stability to the body. The articular cartilage, which is the tissue that lines the joints, is a vital component of the vertebrae, as it helps to cushion the joints and reduce the impact on the surrounding bone.

VRTN is a transmembrane protein that is expressed in the articular cartilage of individuals with OA2. It is composed of four structural domains: a N-terminus, a T-terminus, a middle domain, and an C-terminus. The N-terminus of VRTN contains a unique farnesylated cysteine residue, which is important for its stability and localization in the articular cartilage.

The middle domain of VRTN contains a series of parallel beta-helices that are responsible for the protein's three-dimensional structure and its ability to interact with other proteins. The C-terminus of VRTN contains a series of coiled regions that are involved in the protein's stability and its ability to interact with the cytoskeleton.

VRTN has been shown to play a key role in the development and maintenance of articular cartilage in individuals with OA2. It is expressed in the articular cartilage of individuals with OA2 and has been shown to be involved in the regulation of cell proliferation, migration, and differentiation.

One of the key functions of VRTN is its role in the regulation of cytoskeletal organization. VRTN has been shown to play a key role in the organization of the cytoskeleton in OA2, and it is involved in the regulation of the actin filament distribution and the distribution of the myosin filaments.

In addition to its role in cytoskeletal organization, VRTN is also involved in the regulation of cellular processes that are important for the development and maintenance of articular cartilage. For example, VRTN has been shown to play a key role in the regulation of cell apoptosis, which is the process by which cells die as a result of environmental or genetic stress.

VRTN has also been shown to play a key role in the regulation of cellular signaling pathways that are important for the development and maintenance of articular cartilage. For example, VRTN has been shown to play a key role in the regulation of the TGF-beta signaling pathway, which is involved in the regulation of cell growth, differentiation, and survival.

In conclusion, VRTN is a protein that is expressed in the articular cartilage of individuals with OA2, and has been shown to play a key role in the development and maintenance of this tissue. Its unique farnesylated cysteine residue, as well as its involvement in cytoskeletal organization, cellular processes, and signaling pathways, make it an attractive target for the development of new treatments for OA2. Further research is needed to fully understand the role of VRTN in the development and treatment of OA2, and to develop safe and effective new treatments for this debilitating and painful disease.

Protein Name: Vertebrae Development Associated

The "VRTN Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about VRTN comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets